This study replicates a meta-analysis which found that when adjusting for pre-medicated levels of depression the drugs increased all cause mortality by 49% for SSRI, 75% for other, and 26% for TCA's.(1). This meta-analysis contained corporate funded studies.
The 2022 study was a very large study containing over 220,000 people.
Pro-drug biases/flaws
1- excluded participants on antidepressant polytherapy
2- In figure 1 they show they excluded people who took "antipsychotics" after being exposed to "antidepressants." Also anyone who used "antimanic" drugs were excluded as well.
3- The "baseline" the 10 year study used occurred after 5 years of antidepressant use (table 1).
Confounders adjusted for:
depression, age; gender; body mass index (BMI); waist/hip ratio; smoking and alcohol intake status; physical activity; parental history of outcome; biochemical and haematological biomarkers (apolipoproteins A and B, vitamin D, triglycerides, haemoglobin A1c); socioeconomic status (accommodation status, number of vehicles per household, employment status, benefits status, urban/rural status, education, household income) and self-reported long-term illness, disability or infirmity
Results:
evidence of a dose–response effect (Table 4) for all-cause mortality, with higher doses associated with an increased risk
Table 3 results:
Use of any "antidepressant" increased mortality by 86% when using the 5 year baseline adjustments
Use of any antidepressant increased mortality by 223% when just the Age and gender are adjusted for.
For comparison smoking tobacco increases all cause mortality by around 79%(3), and smokers generally have 10+ year shorter lifespans.
Another study that occurred in those 65 years and older replicated this new study as well(3).
(1) https://www.cambridge.org/core/journals ... 155E72931F
(2) https://www.madinamerica.com/2017/10/an ... udy-finds/
(3) https://www.bmj.com/content/343/bmj.d4551
(4) https://www.ncbi.nlm.nih.gov/pmc/articl ... ollow%2Dup.
News
Site map
SitemapIndex
RSS Feed